Liver Diseases: From Bench to Bedside

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 May 25

PMID 38791491

Authors

Tatsuo Kanda

Reina Sasaki-Tanaka

Shuji Terai

Affiliations

Soon will be listed here.

Abstract

The human genome encodes at least 500 protein kinases, and among them, there are at least 90 tyrosine kinases [...].

References

Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes J, Hughes T . Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023; 37(3):617-626. PMC: 9991909. DOI: 10.1038/s41375-023-01829-9. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

Bouchard M, Puro R, Wang L, Schneider R . Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. J Virol. 2003; 77(14):7713-9. PMC: 161925. DOI: 10.1128/jvi.77.14.7713-7719.2003. View

Ribeiro da Cunha M, Marques T . A Case of Hepatitis E Persistence in a Patient With Myelofibrosis Under Ruxolitinib. ACG Case Rep J. 2021; 8(11):e00674. PMC: 8608255. DOI: 10.14309/crj.0000000000000674. View

Pushpakom S, Iorio F, Eyers P, Jane Escott K, Hopper S, Wells A . Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018; 18(1):41-58. DOI: 10.1038/nrd.2018.168. View

Schlevogt B, Kinast V, Reusch J, Kerkhoff A, Praditya D, Todt D . Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment. Pathogens. 2019; 8(3). PMC: 6789582. DOI: 10.3390/pathogens8030129. View

Mustafayev K, Torres H . Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin Microbiol Infect. 2022; 28(10):1321-1327. DOI: 10.1016/j.cmi.2022.02.042. View

Wang R, Xu Z, Tian J, Liu Q, Dong J, Guo L . Pterostilbene inhibits hepatocellular carcinoma proliferation and HBV replication by targeting ribonucleotide reductase M2 protein. Am J Cancer Res. 2021; 11(6):2975-2989. PMC: 8263682. View

Chiu C, Ahmed S, Thomas S, Wang L, Mustafayev K, Fayad L . Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk. 2023; 23(8):610-615. PMC: 11441351. DOI: 10.1016/j.clml.2023.04.006. View

10.

Chandra S, Tan E, Empeslidis T, Sivaprasad S . Tyrosine Kinase Inhibitors and their role in treating neovascular age-related macular degeneration and diabetic macular oedema. Eye (Lond). 2023; 37(18):3725-3733. PMC: 10697959. DOI: 10.1038/s41433-023-02610-z. View

11.

Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T . The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017; 9(391). DOI: 10.1126/scitranslmed.aaf3962. View

12.

Sasaki-Tanaka R, Masuzaki R, Okamoto H, Shibata T, Moriyama M, Kogure H . Drug Screening for Hepatitis A Virus (HAV): Nicotinamide Inhibits c-Jun Expression and HAV Replication. J Virol. 2023; 97(2):e0198722. PMC: 9973044. DOI: 10.1128/jvi.01987-22. View

13.

Laforgia M, Marech I, Nardulli P, Calabro C, Gadaleta C, Ranieri G . An evaluation of masitinib for treating systemic mastocytosis. Expert Opin Pharmacother. 2019; 20(13):1539-1550. DOI: 10.1080/14656566.2019.1645121. View

14.

Napodano C, Ciasca G, Chiusolo P, Pocino K, Gragnani L, Stefanile A . Serological and Molecular Characterization of Hepatitis C Virus-Related Cryoglobulinemic Vasculitis in Patients without Cryoprecipitate. Int J Mol Sci. 2023; 24(14). PMC: 10380893. DOI: 10.3390/ijms241411602. View

15.

Kanda T, Nakamoto S, Wu S, Nakamura M, Jiang X, Haga Y . Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus. J Clin Transl Hepatol. 2015; 3(3):205-10. PMC: 4663202. DOI: 10.14218/JCTH.2015.00016. View

16.

Kanda T, Sasaki-Tanaka R, Masuzaki R, Matsumoto N, Okamoto H, Moriyama M . Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication. Int J Mol Sci. 2021; 22(14). PMC: 8303476. DOI: 10.3390/ijms22147420. View

17.

Sasaki-Tanaka R, Shibata T, Moriyama M, Kogure H, Hirai-Yuki A, Okamoto H . Masitinib Inhibits Hepatitis A Virus Replication. Int J Mol Sci. 2023; 24(11). PMC: 10253910. DOI: 10.3390/ijms24119708. View

18.

Sunder S, Sharma U, Pokharel S . Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023; 8(1):262. PMC: 10326056. DOI: 10.1038/s41392-023-01469-6. View

19.

Haj Mohamad Ebrahim Ketabforoush A, Chegini R, Barati S, Tahmasebi F, Moghisseh B, Joghataei M . Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomed Pharmacother. 2023; 160:114378. DOI: 10.1016/j.biopha.2023.114378. View

20.

Himmelsbach K, Sauter D, Baumert T, Ludwig L, Blum H, Hildt E . New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut. 2009; 58(12):1644-53. DOI: 10.1136/gut.2009.182212. View